Vanda Pharmaceuticals | VNDA - Operating Expenses


Vanda Pharmaceuticals reported $466M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Anika Therapeutics USD 29.97M 116.84M Dec/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
J&J USD 17.44B 1.53B Mar/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.54B 259M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 10.51B 1.21B Dec/2025
Takeda JPY 1.02T 400.98B Dec/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025
Veracyte USD 116M 7.24M Dec/2025